RE: ApoA-I White Paper - April 2, 2007That white paper contains some very bold statements. We're seeing similarly bold statements from others involved with RVX like Rader.
Consider the following quote from the white paper (the emphasis is mine):
Resverlogix Corp. (RVX) has discovered novel small molecules that increase the production of andogenous ApoA-I. This physiological approach that targets the patients own liver and small intestine to increase the transcription, synthesis, and secretion of ApoA-I, feeds new ApoA-I particles or nascent HDL particles into the reverse cholesterol transport pathway. The parallels with the ApoA-I infusion therapies are obvious. While the former are infusion therapies for short term treatment the Resverlogix small molecules provide permanent ApoA-I increase for chronic treatment. Using this approach, plaque is rapidly removed from the artery to the liver for elimination.
These are rather emphatic statements, including, "plaque is rapidly removed from the artery to the liver for elimination."
So if RVX has produced a drug that up-regulates APO-A1 and therefore nascent HDL particles, and if that drug has been selected from thousands upon thousands of candidates derived from scaffolds produced from the broad computer-modeled creation of compounds, and tested and therefore discovered by the patented assaying technology, and if the resulting compounds mimic endogenous processes and are protected by patent...
...how will anybody else get into the business of up-regulation of APO-A1 without coming to RVX?
This will not be like the statins where a slight modification of the chemistry still works and can be patented. RVX owns all the modifications too.
So is there another way? For instance, is there a down-regulator of APO-A1, the removal or suppression of which would allow APO-A1 to increase? Haven't heard of it, not yet, anyhow. CETP is biting the dust. Atherogenics is down for the count and Liponex pretty much out cold.
Nope, feeling pretty good, thanks...